Literature DB >> 15847620

HCV viremia is associated with drug use in young HIV-1 and HCV coinfected pregnant and non-pregnant women.

Georgia B Nikolopoulou1, Marek J Nowicki, Wenbo Du, James Homans, Alice Stek, Francoise Kramer, Andrea Kovacs.   

Abstract

AIMS: Vertical transmission of HCV is increased among HIV-1/HCV coinfected women and is related to HCV viral load. In this study we assessed clinical and demographic factors associated with HCV viremia in a cohort of young pregnant and non-pregnant mothers coinfected with HIV-1.
DESIGN: A cross-sectional clinic-based study nested within a prospective cohort study.
METHODS: From 1988 to 2000, HIV-1 + pregnant and non-pregnant women with children followed in a large maternal, child and adolescent HIV-1 clinic were evaluated for HCV infection using EIA 3.0. HCV RNA levels were determined for HCV antibody + women using polymerase chain reaction. Demographic and clinical characteristics between HCV-RNA(+) and HCV-RNA(-) women and between pregnant and non-pregnant HIV-1/HCV coinfected women were compared using univariate and multivariate analyses.
FINDINGS: Among 359 HIV-1(+) women, 84 (23%) were HCV-ab + and 49/84 (58%) had detectable HCV-RNA in plasma. Median age was 31. CD4 counts, HIV-1 RNA levels and demographic characteristics were similar for viremic and non-viremic women and pregnant and non-pregnant women. However, viremic women were more likely to report a history of (88% versus 43%; P < 0.001) or active injection drug use (AIDU) (83% versus 29%; P < 0.001). Logistic regression analysis showed that HCV viremia was associated significantly with AIDU (adjusted OR: 15.17; 95% CI: 3.56, 64.56) after adjusting for age, race, number of sexual partners, pregnancy status, CD4 counts and HIV-1 viral load.
CONCLUSION: In this cohort of young HIV-1 and HCV coinfected women, HCV viremia was associated strongly with active injection drug use, perhaps due to reinfection or reactivation of HCV. Thus, careful evaluation for HCV infection and counseling related to drug use may be necessary.

Entities:  

Mesh:

Year:  2005        PMID: 15847620      PMCID: PMC3118993          DOI: 10.1111/j.1360-0443.2005.01054.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  53 in total

Review 1.  Hepatitis C and human immunodeficiency virus infection.

Authors:  David L Thomas
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

3.  Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs.

Authors:  Massimo Resti; Chiara Azzari; Luisa Galli; Giovanna Zuin; Raffaella Giacchino; Flavia Bortolotti; Matilde Marcellini; Maria Moriondo; Maurizio de Martino; Alberto Vierucci
Journal:  J Infect Dis       Date:  2002-02-14       Impact factor: 5.226

4.  Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention.

Authors:  Miriam J Alter; Wendi L Kuhnert; Lyn Finelli
Journal:  MMWR Recomm Rep       Date:  2003-02-07

5.  Clearance of hepatitis C virus after newly acquired infection in injection drug users.

Authors:  Marianne Jauncey; Joanne M Micallef; Stuart Gilmour; Janaki Amin; Peter A White; William Rawlinson; John M Kaldor; Ingrid van Beek; Gregory J Dore
Journal:  J Infect Dis       Date:  2004-08-18       Impact factor: 5.226

6.  Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood.

Authors:  Christoph Steininger; Michael Kundi; Gerlinde Jatzko; Herbert Kiss; Andreas Lischka; Heidemarie Holzmann
Journal:  J Infect Dis       Date:  2003-01-08       Impact factor: 5.226

7.  Lack of protective immunity against reinfection with hepatitis C virus.

Authors:  P Farci; H J Alter; S Govindarajan; D C Wong; R Engle; R R Lesniewski; I K Mushahwar; S M Desai; R H Miller; N Ogata
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

8.  Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.

Authors:  Jeffrey J Post; Yong Pan; Anthony J Freeman; Charles E Harvey; Peter A White; Patricia Palladinetti; Paul S Haber; George Marinos; Michael H Levy; John M Kaldor; Kate A Dolan; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson
Journal:  J Infect Dis       Date:  2004-04-26       Impact factor: 5.226

9.  Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.

Authors:  Sarah L George; Jenny Gebhardt; Donna Klinzman; Mathew B Foster; Kevin D Patrick; Warren N Schmidt; Beth Alden; Michael A Pfaller; Jack T Stapleton
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

10.  Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.

Authors:  A H Mohsen; P J Easterbrook; C Taylor; B Portmann; R Kulasegaram; S Murad; M Wiselka; S Norris
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.